Section II: Object
II.1)Scope of the procurement
II.1.1)Title:
2020-3-76 MODIF. DE PRÓRROGA SUMINISTRO DEXTANDI 40 MG., MEDICAMENTOS EXCLUSIVOS DE "ASTELLAS PHARMA, S.A” PARA EL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE
Reference number: 2020-3-76
II.1.2)Main CPV code
33600000 Pharmaceutical products
II.1.3)Type of contract
Supplies
II.2)Description
II.2.1)Title:
XTANDI 40 MG COMPRIMI-DOS RECUBIERTOS CON PELICULA, 112 comprimidos
Lot No: 1
II.2.2)Additional CPV code(s)
33600000 Pharmaceutical products
II.2.3)Place of performance
NUTS code: ES300 Madrid
II.2.4)Description of the procurement at the time of conclusion of the
contract:
2020-3-76 SUMINISTRO DE XTANDI 40 MG., MEDICAMENTOS DE DISTRIBUCIÓN EXCLUSIVA DE LA FIRMA "ASTELLAS PHARMA, S.A.” PARA EL TRATAMIENTO DE PACIENTES CON CÁNCER DE PRÓSTATA
METASTÁTICO, CON DESTINO AL SERVICIO DE FARMACIA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE.
II.2.7)Duration of the contract, framework agreement, dynamic purchasing system or
concession
Duration in months: 24
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
Section V: Award of contract/concession
Title:
SUMINISTRO XTANDI 40 MG., MEDICAMENTOS EXCLUSIVOS DE "ASTELLAS PHARMA, S.A.” PARA EL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE
V.2)Award of contract/concession
V.2.1)Date of conclusion of the contract/concession award decision:
16/04/2021
V.2.2)Information about tenders
The contract/concession has been awarded to a group of economic operators: no
V.2.3)Name and address of the contractor/concessionaire
Official name: ASTELLAS PHARMA, S.A.
Town: BARCELONA
NUTS code: ES300 Madrid
Country: Spain
The contractor/concessionaire is an SME: no
V.2.4)Information on value of the contract/lot/concession (at the time of conclusion
of the contract;excluding VAT)
Total value of the procurement: 1 178 450.00 EUR
Section VI: Complementary information
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
Official name: SERVICIO MADRILEÑO DE SALUD - HOSPITAL UNIVERSITARIO 12 DE OCTUBRE.
Postal address: AVENIDA DE CÓRDOBA, SIN NÚMERO
Town: MADRID
Postal code: 28041
Country: Spain
Telephone: +34 913908913/8552
Fax: +34 913908181
VI.4.2)Body responsible for mediation procedures
Official name: NO PROCEDE
Town: Madrid
Country: Spain
VI.4.4)Service from which information about the review procedure may be
obtained
Official name: HOSPITAL UNIVERSITARIO 12 DE OCTUBRE.
Postal address: AVENIDA DE CÓRDOBA, SIN NÚMERO
Town: MADRID
Postal code: 28041
Country: Spain
Telephone: +34 913908913/8552
VI.5)Date of dispatch of this notice:
31/10/2023
Section VII: Modifications to the contract/concession
VII.1)Description of the procurement after the modifications
VII.1.1)Main CPV code
33600000 Pharmaceutical products
VII.1.2)Additional CPV code(s)
VII.1.3)Place of performance
NUTS code: ES300 Madrid
VII.1.4)Description of the procurement:
SUMINISTRO DE XTANDI 40 MG MEDICAMENTOS DE DISTRIBUCIÓN EXCLUSIVA DE LA FIRMA ASTELLAS PHARMA, S.A. PARA EL SERVICIO DE FARMACIA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE
VII.1.5)Duration of the contract, framework agreement, dynamic purchasing system or
concession
Start: 01/05/2023
End: 18/04/2025
VII.1.6)Information on value of the contract/lot/concession (excluding VAT)
Total value of the contract/lot/concession: 1 085 384.26 EUR
VII.1.7)Name and address of the contractor/concessionaire
Official name: ASTELLAS PHARMA, S.A.
Town: Barcelona
NUTS code: ES511 Barcelona
Country: Spain
The contractor/concessionaire is an SME: no
VII.2)Information about modifications
VII.2.1)Description of the modifications
Nature and extent of the modifications (with indication of possible earlier changes to the contract):
Modificación en menor importe del lote 1 de la prórroga del contrato (Xtandi 40 mg comprimidos recubiertos con película, 112 comprimidos) con efectividad a partir del 01 de mayo
de 2023.
VII.2.2)Reasons for modification
Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee (Art. 43(1)(c) of Directive 2014/23/EU, Art. 72(1)(c) of Directive
2014/24/EU, Art. 89(1)(c) of Directive 2014/25/EU)
Description of the circumstances which rendered the modification necessary and explanation of the unforeseen nature of these circumstances:
Modificación en menor importe del lote 1 de la prórroga del contrato (Xtandi 40 mg comprimidos recubiertos con película, 112 comprimidos) con efectividad a partir del 01 de mayo
de 2023.
VII.2.3)Increase in price
Updated total contract value before the modifications (taking into account possible earlier contract modifications and price adaptions and, in the case of Directive 2014/23/EU,
average inflation in the Member State concerned)
Value excluding VAT: 1 178 450.00 EUR
Total contract value after the modifications
Value excluding VAT: 1 085 384.26 EUR